The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Open accessAbstract
Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilizing cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase 3 trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) without HBsAg loss, 6 months after discontinuation of treatment would be an intermediate goal. Demonstrated validity in predicting sustained HBsAg loss was considered the most appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-positive and HBeAg-negative chronic hepatitis, treatment-naïve or virally suppressed on nucleos(t)ide analogues. A hepatitis flare associated with increase in bilirubin or INR should prompt temporary or permanent cessation of investigational treatment. New treatments must be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase 3 trials for hepatitis D virus (HDV) co-infection should be undetectable serum HDV RNA 6 months after stopping treatment. On treatment HDV RNA suppression associated with normalization of ALT is considered an intermediate goal. Conclusion: For HBV 'functional cure', sustained HBsAg loss with undetectable HBV DNA after completion of treatment is the primary goal and sustained undetectable HBV DNA without HBsAg loss after stopping treatment an intermediate goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Self-citationTerrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Self-citationAASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Self-citationMarcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Self-citationMaster Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection
Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., Cavalli, A., Missale, G., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02844-06 · Cited by 920
Self-citationSpecific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., et al. (2014) · Science · doi:10.1126/science.1243462 · Cited by 893
Self-citationAdaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829
Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., et al. (2013) · Hepatology · doi:10.1002/hep.26180 · Cited by 710
Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., Petersen, J., Raimondo, G., Dandri, M., & Levrero, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58847 · Cited by 577
Self-citationUpdate of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572
Self-citationHepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
Decorsière, A., Mueller, H., van Breugel, P. C., Abdul, F., Gerossier, L., Beran, R. K., Livingston, C. M., Niu, C., Fletcher, S. P., Hantz, O., et al. (2016) · Nature · doi:10.1038/nature17170 · Cited by 551
Wooddell, C. I., Yuen, M.-F., Chan, H. L.-Y., Gish, R. G., Locarnini, S. A., Chavez, D., Ferrari, C., Given, B. D., Hamilton, J., Kanner, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0241 · Cited by 490
Self-citationFisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., Cavallo, M. C., Silini, E. M., Andreone, P., Missale, G., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.052 · Cited by 488
Self-citationPeginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
Wedemeyer, H., Yurdaydìn, C., Dalekos, G. N., Erhardt, A., Çakaloğlu, Y., Değertekin, H., Gürel, S., Zeuzem, S., Zachou, K., Bozkaya, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0912696 · Cited by 488
Self-citationAgarwal, K., Brunetto, M., Seto, W. K., Lim, Y.-S., Fung, S., Marcellin, P., Ahn, S. H., Izumi, N., Chuang, W., Bae, H., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.039 · Cited by 428
Self-citationSato, S., Li, K., Kameyama, T., Hayashi, T., Ishida, Y., Murakami, S., Watanabe, T., Iijima, S., Sakurai, Y., Watashi, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.016 · Cited by 413
Yuen, M., Wong, D. K., Fung, J., Ip, P., But, D., Hung, I., Lau, K., Yuen, J. C., & Lai, C. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.008 · Cited by 409
Bogomolov, P., Alexandrov, A., Voronkova, N., Macievich, M., Kokina, K., Petrachenkova, M., Lehr, T., Lempp, F. A., Wedemeyer, H., Haag, M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.016 · Cited by 402
Self-citationLanford, R. E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V. L., Brasky, K. M., Fosdick, A., Frey, C. R., Zheng, J., Wolfgang, G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.003 · Cited by 377
The role of quantitative hepatitis B surface antigen revisited
Cornberg, M., Wong, V. W.-S., Locarnini, S., Brunetto, M., Janssen, H. L. A., & Chan, H. L.-Y. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.009 · Cited by 372
Self-citationStrategies to Inhibit Entry of HBV and HDV Into Hepatocytes
Urban, S., Bartenschlager, R., Kubitz, R., & Zoulim, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.030 · Cited by 361
Self-citationHadziyannis, S. J., Sevastianos, V., Rapti, I., Vassilopoulos, D., & Hadziyannis, E. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.039 · Cited by 347
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.008 · Cited by 344
Self-citationFisicaro, P., Barili, V., Montanini, B., Acerbi, G., Ferracin, M., Guerrieri, F., Salerno, D., Boni, C., Massari, M., Cavallo, M. C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4275 · Cited by 341
Self-citationYip, T. C.-F., Wong, G. L.-H., Chan, H. L.-Y., Tse, Y.-K., Lam, K. L.-Y., Lui, G. C.-Y., & Wong, V. W.-S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.014 · Cited by 318
Self-citationCRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N. (2015) · Scientific Reports · doi:10.1038/srep10833 · Cited by 304
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Hepatology · doi:10.1002/hep.29323 · Cited by 303
Self-citationLate HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta
Heidrich, B., Yurdaydın, C., Kabaçam, G., Ratsch, B. A., Zachou, K., Bremer, B., Dalekos, G. N., Erhardt, A., Tabak, F., Yalcin, K., et al. (2014) · Hepatology · doi:10.1002/hep.27102 · Cited by 301
Self-citationTargeting Hepatitis B Virus With CRISPR/Cas9
Seeger, C., & Sohn, J. A. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.68 · Cited by 294
Chu, C., Hung, S.-J., Lin, J., Tai, D., & Liaw, Y. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.040 · Cited by 287
Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S. L., Haynes-Williams, V., Winters, M. A., Subramanya, G., Cooper, S. L., Pinto, P., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00074-2 · Cited by 269
Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., Möller, I., Seiz, P., Glebe, D., Wang, B., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003856 · Cited by 251
Cai, D., Mills, C., Yu, W., Yan, R., Aldrich, C. E., Saputelli, J. R., Mason, W. S., Xu, X., Guo, J.-T., Block, T. M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-12 · Cited by 220
Mak, L. ‐., Wong, D. K. ‐., Cheung, K. ‐., Seto, W. ‐., Lai, C. ‐., & Yuen, M. ‐. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14376 · Cited by 217
Kim, W. R., Loomba, R., Berg, T., Aguilar Schall, R. E., Yee, L. J., Dinh, P. V., Flaherty, J. F., Martins, E. B., Therneau, T. M., Jacobson, I., et al. (2015) · Cancer · doi:10.1002/cncr.29537 · Cited by 212
Self-citationKim, J. H., Sinn, D. H., Kang, W., Gwak, G., Paik, Y., Choi, M. S., Lee, J. H., Koh, K. C., & Paik, S. W. (2017) · Hepatology · doi:10.1002/hep.28916 · Cited by 211
Menne, S., Tumas, D. B., Liu, K. H., Thampi, L., AlDeghaither, D., Baldwin, B. H., Bellezza, C. A., Cote, P. J., Zheng, J., Halcomb, R., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.026 · Cited by 208
Qasim, W., Brunetto, M., Gehring, A. J., Xue, S.-A., Schurich, A., Khakpoor, A., Zhan, H., Ciccorossi, P., Gilmour, K., Cavallone, D., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.001 · Cited by 208
Self-citationJanssen, H. L. A., Brunetto, M. R., Kim, Y. J., Ferrari, C., Massetto, B., Nguyen, A.-H., Joshi, A., Woo, J., Lau, A. H., Gaggar, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.027 · Cited by 203
Self-citationDurantel, D., & Zoulim, F. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.016 · Cited by 200
Self-citationSpontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
Liu, J., Yang, H.-I., Lee, M.-H., Lu, S.-N., Jen, C.-L., Batrla-Utermann, R., Wang, L.-Y., You, S.-L., Hsiao, C. K., Chen, P.-J., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305785 · Cited by 195
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
Gane, E. J., Lim, Y.-S., Gordon, S. C., Visvanathan, K., Sicard, E., Fedorak, R. N., Roberts, S., Massetto, B., Ye, Z., Pflanz, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.037 · Cited by 190
Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection
Gehring, A. J., & Protzer, U. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.10.032 · Cited by 185
T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes
Bohne, F., Chmielewski, M. M., Ebert, G., Wiegmann, K., Kürschner, T., Schulze, A., Urban, S., Krönke, M., Abken, H., & Protzer, U. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.002 · Cited by 183
Key design considerations for adaptive clinical trials: a primer for clinicians
Thorlund, K., Haggstrom, J., Park, J. J., & Mills, E. J. (2018) · BMJ · doi:10.1136/bmj.k698 · Cited by 182
Lok, A. S., Pan, C. Q., Han, S.-H. B., Trinh, H. N., Fessel, W. J., Rodell, T., Massetto, B., Lin, L., Gaggar, A., Subramanian, G. M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.016 · Cited by 178
Self-citationMaasoumy, B., Wiegand, S. B., Jaroszewicz, J., Bremer, B., Lehmann, P., Deterding, K., Taranta, A., Manns, M. P., Wedemeyer, H. H., Glebe, D., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.02.010 · Cited by 162
Self-citationWang, J., Yu, Y., Li, G., Shen, C., Meng, Z., Zheng, J., Jia, Y., Chen, S., Zhang, X., Zhu, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.08.021 · Cited by 161
Butler, E. K., Gersch, J., McNamara, A., Luk, K., Holzmayer, V., de Medina, M., Schiff, E., Kuhns, M., & Cloherty, G. A. (2018) · Hepatology · doi:10.1002/hep.30082 · Cited by 160
Boni, C., Vecchi, A. L., Rossi, M., Laccabue, D., Giuberti, T., Alfieri, A., Lampertico, P., Grossi, G., Facchetti, F., Brunetto, M. R., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.030 · Cited by 157
Self-citationSeto, W., Wong, D. K.-H., Fung, J., Huang, F., Liu, K. S.-H., Lai, C., & Yuen, M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12739 · Cited by 140
A novel orally available small molecule that inhibits hepatitis B virus expression
Mueller, H., Wildum, S., Luangsay, S., Walther, J., Lopez, A., Tropberger, P., Ottaviani, G., Lu, W., Parrott, N. J., Zhang, J. D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.014 · Cited by 133
Self-citationInhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx–DDB1 Interaction
Sekiba, K., Otsuka, M., Ohno, M., Yamagami, M., Kishikawa, T., Suzuki, T., Ishibashi, R., Seimiya, T., Tanaka, E., & Koike, K. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.010 · Cited by 132
STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus
Guo, F., Han, Y., Zhao, X., Wang, J., Liu, F., Xu, C., Wei, L., Jiang, J., Block, T. M., Guo, J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04321-14 · Cited by 130
Shimura, S., Watashi, K., Fukano, K., Peel, M. R., Sluder, A. E., Kawai, F., Iwamoto, M., Tsukuda, S., Takeuchi, J. S., Miyake, T., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.009 · Cited by 130
Chang, M., Liaw, Y., & Hadziyannis, S. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13272 · Cited by 129
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
Yurdaydın, C., Abbas, Z., Buti, M., Cornberg, M., Esteban, R., Etzion, O., Gane, E. J., Gish, R. G., Glenn, J. S., Hamid, S. S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.022 · Cited by 123
Self-citationWedemeyer, H. H., Schöneweis, K., Bogomolov, P. O., et al. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30141-0 · Cited by 123
Self-citationMaini, M. K., & Pallett, L. J. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30007-4 · Cited by 113
Self-citationYang, H., Tsou, H., Pei, S., Chang, C., Chen, J.-H., Yao, M., Lin, S., Lin, J., Yuan, Q., Xia, N., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.033 · Cited by 94
Jacobi, F., Wild, K., Smits, M., Zoldan, K., Csernalabics, B., Flecken, T., Lang‐Meli, J., Ehrenmann, P., Emmerich, F., Hofmann, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.016 · Cited by 79
Isorce, N., Lucifora, J., Zoulim, F., & Durantel, D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.08.008 · Cited by 76
Self-citationJavanbakht, H., Mueller, H., Walther, J., Zhou, X., Lopez, A., Pattupara, T., Blaising, J., Pedersen, L., Albæk, N., Jackerott, M., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.005 · Cited by 76
Shinkai, N., Matsuura, K., Sugauchi, F., Watanabe, T., Murakami, S., Iio, E., Ogawa, S., Nojiri, S., Joh, T., & Tanaka, Y. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00726-13 · Cited by 74
Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection
Liu, Y., Jiang, M., Xue, J., et al. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-0966-4 · Cited by 73
Gill, U. S., Peppa, D., Micco, L., Singh, H. D., Carey, I., Foster, G. R., Maini, M. K., & Kennedy, P. T. F. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005788 · Cited by 71
Self-citationKorolowicz, K. E., Iyer, R. P., Czerwinski, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161313 · Cited by 71
Han, X., Zhou, C., Jiang, M., Wang, Y., Wang, J., Cheng, Z., Wang, M., Liu, Y., Liang, C., Wang, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01245 · Cited by 71
Sekiba, K., Otsuka, M., Ohno, M., Yamagami, M., Kishikawa, T., Seimiya, T., Suzuki, T., Tanaka, E., Ishibashi, R., Funato, K., et al. (2018) · Hepatology · doi:10.1002/hep.30491 · Cited by 57
Kuhnhenn, L., Jiang, B., Kubesch, A., Vermehren, J., Knop, V., Süsser, S., Dietz, J., Carra, G., Finkelmeier, F., Grammatikos, G., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14636 · Cited by 42
Han, K., Cremer, J., Elston, R., Oliver, S. D., Baptiste‐Brown, S., Chen, S., Gardiner, D., Davies, M., Saunders, J., Hamatake, R. K., et al. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.670 · Cited by 42
Deguchi, M., Kagita, M., Yoshioka, N., Tsukamoto, H., Takao, M., Tahara, K., Maeda, I., Hidaka, Y., Yamauchi, S., Kaneko, A., et al. (2017) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22334 · Cited by 34
Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)
Kullak-Ublick, G. A., Merz, M., Griffel, L. H., Kaplowitz, N., & Watkins, P. B. (2014) · Drug Safety · doi:10.1007/s40264-014-0186-3 · Cited by 33
Jacobson, I. M., Washington, M. K., Buti, M., Thompson, A. J. V., Afdhal, N. H., Flisiak, R., Akarca, U. S., Tchernev, K. G., Jr., Flaherty, J. F., Schall, R. A., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.01.032 · Cited by 31
Self-citationT-cell therapy for chronic viral hepatitis
Bertoletti, A., Tan, A. T., & Koh, S. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.011 · Cited by 28
Enomoto, H., Aizawa, N., Nishikawa, H., Ikeda, N., Sakai, Y., Takata, R., Hasegawa, K., Nakano, C., Nishimura, T., Yoh, K., et al. (2016) · Medicine · doi:10.1097/md.0000000000003565 · Cited by 26
Article Commentary: ImPortance of IP-10 in Hepatitis B
Cornberg, M., & Wiegand, S. B. (2015) · Antiviral Therapy · doi:10.3851/imp3014 · Cited by 16
Self-citationLee, A. C. H., Heyes, J., Ye, X., Holland, R., Thi, E. P., Wood, M., Judge, A. D., Snead, N. M., Martin, A., & Sofia, M. J. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30254-x · Cited by 10
Cited by
Jeng, W.-J., Papatheodoridis, G. V., & Lok, A. S. F. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01468-4 · Cited by 561
Self-citationEASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Self-citationEASL Clinical Practice Guidelines on hepatitis delta virus
Brunetto, M. R., Ricco, G., Negro, F., Wedemeyer, H., Yurdaydin, C., Asselah, T., Papatheodoridis, G., Gheorghe, L., Agarwal, K., Farci, P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.001 · Cited by 294
Self-citationEfficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Yuen, M.-F., Lim, S.-G., Plesniak, R., Tsuji, K., Janssen, H. L. A., Pojoga, C., Gadano, A., Popescu, C. P., Stepanova, T., Asselah, T., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210027 · Cited by 280
Self-citationHow to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong, G. L. H., Gane, E., & Lok, A. S. F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.024 · Cited by 272
Self-citation
Metadata
- Authors
- Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., Dandri, M., Dusheiko, G., Feld, J. J., Ferrari, C., Ghany, M., Janssen, H. L. A., Kennedy, P., Lampertico, P., Liang, J., Locarnini, S., Maini, M. K., Mishra, P., Papatheodoridis, G., Petersen, J., Schlottmann, S., Wang, S., & Wedemeyer, H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 72
- Issue
- 3
- Pages
- 539-557
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2984221112
- Cited by
- 366
- References
- 79
- FWCI
- 27.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.